What Really Mattered With Editas Medicine's Q1 Update
Editas Medicine (NASDAQ: EDIT) entered 2021 with tremendous momentum. The company announced a Q1 net loss of $56.7 million, or $0.86 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Editas posted a GAAP net loss of $37.7 million, or $0.69 per share.